Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
iwCAR-T 2025
The 7th International Workshop on CAR-T and Bispecifics (iwCAR-T)
11–13 April 2025 | Miami, FL
The 7th International Workshop on CAR-T and Bispecifics (iwCAR-T) took place in Miami, FL, on April 11-13, 2025, bringing together leading clinical researchers to discuss the latest advances in CAR therapies and bispecific antibodies.
The iwCAR-T and bispecifics 2025 Workshop was supported by Genetech, Johnson & Johnson, Kite, Bristol Myers Squibb, A2 BIO, Galápagos, Miltenyi Biomedicine, Caribou Biosciences, nkarta, Novartis, Legend Biotech, Immatics, Autolus, Biontech and Iovance biotherapeutics. Supporters have no influence over the production of content.
Keynote lecture
How solid CAR-T targeting has evolved
Prasad Adusumilli Memorial Sloan Kettering Cancer Center, New York City, NY, United States
CARs targeting cell surface proteins (part I)
DLL3-CAR-T for SCLC
Michael Gormally Memorial Sloan Kettering Cancer Center, New York City, NY, United States
GCC19 CAR-T therapy for refractory colorectal cancer: Overcoming challenges in expansion and persistence
Benjamin Schlechter Dana-Farber Cancer Institute, Boston, MA, United States
Updates on logic-gated CAR T-cell therapies in pancreatic cancer
Joel Randolph Hecht UCLA Health, Los Angeles, CA, United States
An update on CAR T-cell therapy for breast and ovarian cancer: A long and winding road
Jennifer Specht University of Washington, Seattle, WA, United States
CARs targeting cell surface proteins (part II)
CLDN6-targeted therapy with CAR T-cells +/- CARVac in relapsed germ cell tumors
Winfried Alsdorf University Medical Center Hamburg-Eppendorf, Hamburg, Germany
hALK.CAR T-cells for relapsed/refractory neuroblastoma
Susanne Baumeister Dana-Farber Cancer Institute, Boston, MA, United States
Cell therapy advances in ovarian cancer: What we know and where we’re headed
Monica Avila Moffitt Cancer Center, Tampa, FL, United States
T-cell engagers and TCRs
Afami-Cel in metastatic synovial sarcoma: The 1st genetically engineered TCR therapy approved for a solid tumor
Mihaela Druta H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, United States
Immunologic targeting of undruggable TP53 hotspot mutations through T-cell receptor gene therapy
Michael Gormally Memorial Sloan Kettering Cancer Center, New York City, NY, United States
Targeting PRAME with TCR T-cells first in melanoma then beyond
Jason Luke University of Pittsburgh, Pittsburgh, PA, PA, United States
TILs across solid tumors
Promising T-cell targets in lung cancers: Trial updates
Ben Creelan Moffitt Cancer Center, Tampa, FL, United States
Coming soon
TIL therapy for GU malignancies
Michael Poch Moffitt Cancer Center, Tampa, FL, United States
Coming soon
Optimizing TIL therapy for melanoma & beyond
Allison Betof Warner Stanford Medicine, Stanford, CA, United States
Coming soon
Novel technologies in solid tumors
Genome-edited anti-GPC3 CAR for hepatoma
Marco Davila Roswell Park Comprehensive Cancer Center, Buffalo, NY, United States
Coming soon
CAR-M: Engineering myeloid cells for solid tumor immunotherapy
Saar Gill University of Pennsylvania, Philadelphia, PA, United States
Coming soon
Advancing T-cell therapies for solid cancers
Saul Priceman Keck School of Medicine of USC, Los Angeles, CA, United States
Coming soon
